Akebia Therapeutics
AKBA
#8668
Rank
A$0.36 B
Marketcap
A$1.33
Share price
6.42%
Change (1 day)
-71.40%
Change (1 year)

Earnings for Akebia Therapeutics (AKBA)

Earnings in 2026 (TTM): -A$27.56 Million

According to Akebia Therapeutics's latest financial reports the company's current earnings are A$0.23 Billion. In 2025 the company made an earning of -A$5.18 Million, an increase over its 2024 earnings that were of -A$96.62 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Akebia Therapeutics from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -A$27.56 Million431.93%
2025 -A$5.18 Million-94.64%
2024 -A$96.62 Million33.68%
2023 -A$72.28 Million-45.12%
2022 -A$0.14 Billion-66.55%
2021 -A$0.4 Billion-26.24%
2020 -A$0.54 Billion33.94%
2019 -A$0.4 Billion66.52%
2018 -A$0.24 Billion123.53%
2017 -A$0.11 Billion-43.34%
2016 -A$0.19 Billion123.58%
2015 -A$84.52 Million63.95%
2014 -A$51.55 Million181.24%
2013 -A$18.33 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Johnson & Johnson
JNJ
A$36.16 B-138,573.43%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
A$21.97 B-84,231.98%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Amgen
AMGN
A$12.64 B-48,535.58%๐Ÿ‡บ๐Ÿ‡ธ USA
Nektar Therapeutics
NKTR
-A$0.22 Billion 711.30%๐Ÿ‡บ๐Ÿ‡ธ USA